ABSTRACT
Elevated immunoglobulin free light chain (FLC) level and abnormal FLC ratio are commonly seen in multiple myeloma (MM) and have prognostic implications. We hypothesized that presence of immunoglobin heavy chain (IgH) translocations leads to unbalanced production of light chains and more extreme abnormalities of FLC, and may explain the prognostic value of FLC. We studied 314 patients with newly diagnosed MM enrolled in a phase III trial, in whom results of fluorescence in situ hybridization testing and data on serum FLC levels were available. Cytogenetic analyses and FLC estimates were performed on stored samples and results were correlated with clinical data. The median ratio (FLC ratio) and the absolute difference (FLC diff) between the involved and uninvolved FLC were higher among those with IgH translocations, especially t(14;16). In multivariate analysis, the prognostic value of FLC estimates on progression-free and overall survival were independent of high-risk IgH translocations t(4;14) and t(14;16). A combination of the risk factors; either abnormal FLC estimate and/or the presence of high-risk IgH translocation, achieved better prognostic stratification. We conclude that patients with IgH translocations have higher FLC levels and abnormal ratios, but the prognostic effect of FLC is only partially explained by translocation status. A system including both these risk factors allows better prediction of outcome.
Subject(s)
Immunoglobulin Heavy Chains/genetics , Immunoglobulin Light Chains/blood , Multiple Myeloma/genetics , Translocation, Genetic , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Humans , In Situ Hybridization, Fluorescence , Multiple Myeloma/blood , Multiple Myeloma/drug therapy , Prognosis , Survival AnalysisSubject(s)
Biomarkers, Tumor/blood , Genes, p53 , Multiple Myeloma/genetics , Mutant Proteins/blood , Tumor Suppressor Protein p53/blood , Chromosomes, Human, Pair 17/genetics , Codon, Nonsense , Cohort Studies , DNA Mutational Analysis , Disease Progression , Follow-Up Studies , Humans , Kaplan-Meier Estimate , Multiple Myeloma/mortality , Prognosis , Proportional Hazards Models , Sequence DeletionABSTRACT
Chromosomal hyperdiploidy is the defining genetic signature in 40-50% of myeloma (MM) patients. We characterize hyperdiploid-MM (H-MM) in terms of its clinical and prognostic features in a cohort of 220 H-MM patients entered into clinical trials. Hyperdiploid-myeloma is associated with male sex, kappa immunoglobulin subtype, symptomatic bone disease and better survival compared to nonhyperdiploid-MM (median overall survival 48 vs 35 months, log-rank P = 0.023), despite similar response to treatment. Among 108 H-MM cases with FISH studies for common genetic abnormalities, survival is negatively affected by the existence of immunoglobulin heavy chain (IgH) translocations, especially those involving unknown partners, while the presence of chromosome 13 deletion by FISH did not significantly affect survival (median overall survival 50 vs 47 months, log-rank P = 0.47). Hyperdiploid-myeloma is therefore a unique genetic subtype of MM associated with improved outcome with distinct clinical features. The existence of IgH translocations but not chromosome 13 deletion by FISH negatively impacts survival and may allow further risk stratification of this population of MM patients.
Subject(s)
Chromosome Deletion , Chromosomes, Human, Pair 13/genetics , Chromosomes, Human, Pair 17/genetics , Immunoglobulin Heavy Chains/genetics , Multiple Myeloma/genetics , Polyploidy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chromosome Aberrations , Female , Follow-Up Studies , Genes, p53/genetics , Humans , Male , Middle Aged , Multiple Myeloma/drug therapy , Prognosis , Randomized Controlled Trials as Topic/statistics & numerical data , Retrospective Studies , Survival Rate , Translocation, Genetic , Treatment OutcomeABSTRACT
Hyperdiploid and non-hyperdiploid multiple myeloma represents distinct biological entities characterized by different patterns of genetic changes. We sought to determine whether ploidy category (non-hyperdiploid versus hyperdiploid) remains stable over time from diagnosis to progression. Of the 43 patients studied (39 by flow cytometry DNA index and 4 by a FISH-based index), only five (12%) altered their ploidy status at progression. In three of these patients, the change may possibly be attributable to technical artifacts because of the low absolute change in DNA index. For those who retain their ploidy subtypes, the DNA index change minimally (3.75+/-4.87%). It would appear that the initiating genetic events underlying hyperdiploid and non-hyperdiploid MM that marks them out as distinct entities continue to dominate and persist during disease evolution and progression.
Subject(s)
DNA, Neoplasm/genetics , Multiple Myeloma/genetics , Ploidies , DNA, Neoplasm/analysis , Disease Progression , Female , Flow Cytometry , Humans , In Situ Hybridization, Fluorescence , Male , Multiple Myeloma/pathologyABSTRACT
Stem cell transplantation was introduced as a new therapeutic modality for amyloidosis. The purpose of the current study was to determine the feasibility and toxicity of stem cell transplantation for amyloidosis in a cooperative group setting in which most participating institutions would have limited experience in managing the disorder. A total of 30 patients with biopsy-proven amyloidosis shown to be immunoglobulin light-chain type were enrolled on this trial. The protocol required mobilization of a minimum of 6 x 10(8) mononuclear cells/kg or 5 x 10(6) CD34(+) cells/kg ideal body weight. These targets had to be achieved within seven collections. Patients with advanced hepatic, renal, or cardiac failure were excluded. End points included objective response rate and overall survival. The secondary end point of the protocol was nonhematologic toxicity. Accrual to the study was faster than expected. The overall response rate (hematologic and organ) was 64%, with three treatment-related deaths. Another patient died before day 30 of sudden cardiac death not treatment related. The median follow-up of surviving patients is 30.3 months. Median survival has not been reached. Stem cell transplantation for selected patients with amyloidosis is feasible in a cooperative group setting. A multicenter phase 3 trial of high-dose therapy is indicated.
Subject(s)
Amyloidosis/therapy , Peripheral Blood Stem Cell Transplantation/methods , Adult , Aged , Amyloidosis/mortality , Antigens, CD34/analysis , Blood Component Removal/methods , Cause of Death , Female , Hematopoietic Stem Cell Mobilization/methods , Humans , Male , Melphalan/therapeutic use , Melphalan/toxicity , Middle Aged , Peripheral Blood Stem Cell Transplantation/adverse effects , Peripheral Blood Stem Cell Transplantation/mortality , Remission Induction , Survival RateABSTRACT
Image intensifier-television-video digitizer (IITVD) systems are commonly used for digital planar image acquisition in radiology. However, the well-known distortions inherent in these systems limit their utility in research and in some clinical applications where quantitatively correct images are required. Software correction techniques have been implemented which restore both the spatial and grey scale quantitative integrity, allowing IITVD systems to be used as analytical research tools. Previously reported and novel correction techniques were used to reduce veiling glare, pincushion distortion, dc bias, and residual shading effects. The results indicate that excellent quantitative integrity can be achieved when these straightforward artifact reduction techniques are employed.